“You may choose to look the other way, but you can never say again that you did not know.”
— William Wilberforce
Pfizer, Inc. has withdrawn its emergency use authorization (EUA) application for its experimental BNT162b2 (also known as “Comirnaty”) messenger RNA (mRNA) COVID-19 biologic (developed in collaboration with Germany’s BioNTech) in India.1 Pfizer was the first pharmaceutical company to apply for an EUA to distribute a COVID biologic in India in 2021. However, India’s regulatory agency […]
A 24-year-old student at Corning Community College in Corning, New York died on Oct. 27, 2021, about six weeks after receiving the second dose of Pfizer/BioNTech’s experimental messenger RNA (mRNA) BNT162b2 (also known as “Comirnaty”) biologic for COVID-19. George Watts Jr., who was healthy and had no underlying medical conditions, was vaccinated in August and […]
Pfizer and BioNTech have requested emergency use authorization (EUA) for doctors to administer two doses of their mRNA COVID-19 biologic to infants as young as six months old. A statement from Pfizer states that the “rolling submission” application was submitted on Feb. 1, 2022 at the request of the U.S. Food and Drug Administration (FDA) […]
A new study conducted by researchers from the U.S. Centers for Disease Control and Prevention (CDC) and several universities and hospitals in the United States shows that the risk of myocarditis (inflammation of the heart muscle) after receiving a messenger RNA (mRNA) COVID-19 biologic is 133 times greater than the normal risk for the condition […]
Based on better than expected sales of its experimental messenger RNA (mRNA) BNT162b2 COVID-19 biologic, New York-based pharmaceutical company Pfizer, Inc. last summer revised projected sales of its experimental drug, also known as “Comirnaty,” from $26 billion to $33.5 billion in 2021. Characterizing second-quarter sales of BNT162b2 as “remarkable,” Pfizer’s chief executive officer (CEO) Albert […]
Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
On Dec. 8, 2021, the White House’s chief medical advisor, Anthony Fauci, MD, suggested he believed it was likely the U.S. government would change the definition of what it meant to be “fully vaccinated” to include booster shots, as well as the original two-shot regimen of the Pfizer/BioNTech and Moderna/NIAID COVID-19 biologics or one shot […]
A former testing site researcher in Texas has alleged that Pfizer’s pre-licensure BNT162b2 (also known as “Comirnaty”) COVID-19 biologic trials included falsification of data, unblinding patients, employing inadequately trained vaccinators, and delays in following up on experimental COVID vaccine adverse reaction reports.1 According to clinical trial researcher Brook Jackson, the incidences occurred during the phase […]
A 26-year-old man in Dunedin, New Zealand died on Nov. 17, 2021 unexpectedly, 12 days after getting the first dose of Pfizer/BioNTech’s experimental messenger RNA (mRNA) BNT162b2 (also known as “Comirnaty”) biologic for COVID-19. Rory James Nairn was vaccinated on Nov. 5 and reportedly began to feel heart palpations or “flutters” a few hours after […]
Based on concerns over a growing number of reports of a blood clotting disorder known as thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Johnson & Johnson/Janssen’s experimental human adenovirus vectored Ad26.COV2.S vaccine, the Advisory Committee on Immunization Practices (ACIP) voted 15-0 on Dec. 16, 2021 to recommend the experimental messenger RNA (mRNA) COVID-19 biologics […]